Tiare Technology v. CVS Health: Mobile-App Patent Claims Dismissed With Prejudice
Tiare Technology asserted three US patents covering mobile-ordering application technology against CVS Health Corp. and CVS Pharmacy, Inc. in the Eastern District of Texas. The parties jointly resolved the dispute in just 126 days, with Tiare’s claims dismissed with prejudice and CVS’s counterclaims dismissed without prejudice — each side bearing its own costs.
Swift with-prejudice exit in the mobile-ordering app patent space
Filed on 14 September 2023 in the Eastern District of Texas, Tiare Technology, Inc. brought a patent infringement action against CVS Health Corp. and CVS Pharmacy, Inc. asserting three issued US patents — US11195224B2, US10157414B2, and US8682729B2 — all directed at mobile-ordering application technology. The Eastern District of Texas is a historically plaintiff-friendly venue frequently selected for patent assertions, making CVS’s rapid resolution all the more commercially significant.
The case closed on 18 January 2024 via a joint motion to dismiss. The court granted the motion: Tiare’s claims were dismissed with prejudice, while CVS’s counterclaims were dismissed without prejudice. The court also ordered each party to bear its own costs, attorneys’ fees, and expenses — a common settlement-adjacent outcome that avoids any finding of exceptional case status under 35 U.S.C. § 285. Notably, this case was a member of a consolidated series, and the lead case (No. 2:23-cv-412) remained open.
A 126-day resolution is considerably shorter than the median patent case in the Eastern District of Texas, suggesting the parties reached agreement before significant litigation costs accumulated. The with-prejudice dismissal of Tiare’s claims is the key commercial outcome: it permanently bars re-litigation of these specific claims against CVS on these patents in this forum. The public record does not disclose whether a licensing arrangement, lump-sum payment, or other commercial consideration drove the settlement, leaving the true resolution terms unknown.
Filing to dismissal in 126 days
126 days — faster than the typical 18–24 month E.D. Texas patent case lifecycle
What the with-prejudice dismissal means for Tiare and CVS
Joint motion to dismiss — a negotiated exit, not a court ruling on merits
The dismissal was triggered by a joint motion filed by both parties, representing that the case had been resolved. This procedural vehicle is standard in settled patent disputes: neither side requires the court to adjudicate infringement or validity. The court’s role was limited to approving the stipulated dismissal, which it did without any substantive merits analysis.
No merits adjudicationTiare’s claims: with prejudice. CVS’s counterclaims: without prejudice.
The asymmetric prejudice terms are significant. Tiare’s infringement claims are dismissed with prejudice, permanently barring Tiare from re-asserting the same claims against CVS on these three patents in this member case. CVS’s counterclaims — which may have included invalidity challenges — are dismissed without prejudice, meaning CVS retains the right to revive them if needed. This structure typically reflects a plaintiff-initiated resolution.
Plaintiff claims permanently barredEach party bears its own costs — no fee-shifting, no § 285 finding
The court ordered each party to bear its own costs, expenses, and attorneys’ fees. Under 35 U.S.C. § 285, a prevailing party in an exceptional patent case may recover attorneys’ fees. The mutual cost-bearing order here suggests neither party sought — or could obtain — an exceptional case finding, consistent with a negotiated resolution reached before extensive briefing on the merits.
No exceptional case findingMember case closed — but lead consolidated case (No. 2:23-cv-412) stays open
This case was one member of a consolidated series. The court’s order closed Case No. 2:23-cv-413 but directed the clerk to maintain the lead case (No. 2:23-cv-412) as open due to live disputes remaining in the broader series. This signals that Tiare’s assertion campaign was broader than a single defendant — the resolution here does not necessarily reflect the outcome against other defendants in the consolidated matter.
Broader litigation series ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Tiare Technology, Inc. | Company | Patent assertion entity — holder of US11195224B2, US10157414B2, and US8682729B2Search in Eureka ↗ |
| Defendant | CVS Health Corp. | Company | CVS Health Corp. and CVS Pharmacy, Inc. — major US retail pharmacy and health services groupSearch in Eureka ↗ |
| Plaintiff counsel | Christian J. Hurt | Attorney | Counsel for Tiare Technology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William Ellsworth Davis , III | Attorney | Counsel for Tiare Technology, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeanne M. Gills | Attorney | Counsel for CVS Health Corp.Search in Eureka ↗ |
| Defendant counsel | Justin Mark Sobaje | Attorney | Counsel for CVS Health Corp.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Texas Eastern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s order grants a joint motion to dismiss, meaning no substantive merits finding was made on infringement or validity. The asymmetric prejudice structure — Tiare’s claims dismissed with prejudice, CVS’s counterclaims without prejudice — is the operative legal consequence. For Tiare, the with-prejudice dismissal forecloses re-litigation of these specific claims against CVS in this member case. For CVS, retaining the without-prejudice posture on counterclaims preserves optionality if Tiare were to pursue related claims in another forum.
US11195224B2, US10157414B2 & US8682729B2 — Mobile-Ordering Application Patents
Tiare Technology asserted three US patents — US11195224B2 (App. No. 16/217798), US10157414B2 (App. No. 15/820195), and US8682729B2 (App. No. 13/543193) — all directed at mobile-ordering application technology. The sequential application numbers suggest a continuation family relationship, with US8682729B2 representing the earliest-filed generation and US11195224B2 the most recent continuation. This family structure is common in software patent portfolios where the original applicant files continuation applications to capture evolving claim scope as the technology matures and commercial adoption grows.
Mobile-ordering application patents sit at the intersection of consumer-facing retail software and backend transaction processing — a space that has seen significant assertion activity as pharmacy, grocery, and food-service operators deployed digital ordering platforms. A three-patent family covering this domain can apply pressure across a wide range of mobile commerce implementations. Companies in retail, pharmacy, and app-based ordering should treat this portfolio as a potential enforcement signal, particularly given that the lead consolidated case remains open and may involve additional defendants in the same sector.
Should your mobile-ordering product team run an FTO against these three patents?
Any company operating a mobile-ordering application — particularly in retail pharmacy, grocery, or consumer services — should assess exposure to the Tiare Technology patent family. The three asserted patents span multiple continuation generations, meaning the claims may have been iteratively broadened to cover a wider range of implementations than the original specification suggests. If your product offers app-based ordering, cart management, or pharmacy-integrated digital commerce, a freedom-to-operate review against this family is warranted before further feature development.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the independent and dependent claims of US11195224B2, US10157414B2, and US8682729B2 simultaneously, surfacing overlap risk and prior art candidates that may support design-around or invalidity arguments. Claim monitoring across this family will also alert your team if Tiare — or any assignee — files further continuations or asserts these patents in the lead consolidated case, giving you early signal before litigation risk materialises.
Run a freedom-to-operate analysis on US11195224B2 to assess your product’s exposure
Run FTO in Eureka →Similar mobile-app patent infringement cases in E.D. Texas
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the retail tech and mobile-app patent landscape
A rapid with-prejudice exit against a major pharmacy retailer raises questions about assertion strategy, patent quality, and enforcement patterns in mobile commerce IP.
E.D. Texas remains the forum of choice for mobile-app patent assertions
Filing in the Eastern District of Texas signals a plaintiff optimising for venue advantage. The 126-day resolution suggests CVS elected not to contest the forum and instead moved to resolve early — a rational response to the cost and uncertainty of E.D. Texas litigation, even for a company of CVS’s scale.
Three-patent assertion bundles increase settlement pressure on defendants
Asserting three patents simultaneously — US11195224B2, US10157414B2, and US8682729B2 — raises the cost and complexity of any invalidity or non-infringement defence. Defendants facing multi-patent assertions in E.D. Texas frequently find early resolution more cost-effective than full litigation, even when confident in their position on the merits.
Tiare v CVS — key questions answered
Tiare Technology, Inc. filed a patent infringement action against CVS Health Corp. and CVS Pharmacy, Inc. in the Eastern District of Texas on 14 September 2023, asserting three mobile-ordering application patents. The case was resolved and dismissed via joint motion on 18 January 2024 — 126 days after filing — with Tiare’s claims dismissed with prejudice and CVS’s counterclaims dismissed without prejudice. Each party bore its own costs.
Tiare asserted US11195224B2, US10157414B2, and US8682729B2 — three patents directed at mobile-ordering application technology. The application numbers (16/217798, 15/820195, and 13/543193) suggest these patents form a continuation family, with US8682729B2 as the earliest-filed member and US11195224B2 as the most recent continuation.
Dismissal with prejudice means Tiare cannot re-file the same infringement claims against CVS on these three patents in this member case. It is a permanent bar to re-litigation of those specific claims, operating as a final adjudication on the merits for preclusion purposes — even though no substantive merits ruling was made by the court.
The asymmetric prejudice terms reflect the negotiated nature of the resolution. CVS’s counterclaims — likely including invalidity or non-infringement defences — were preserved on a without-prejudice basis, meaning CVS retains the option to revive them if necessary. This structure typically arises when a plaintiff initiates settlement and the defendant agrees to dismiss its defences conditionally, without forfeiting them entirely.
Case No. 2:23-cv-00413 (the member case involving CVS) is closed. However, the court’s order notes that the lead consolidated case, No. 2:23-cv-412, remains open due to live disputes involving other defendants. Tiare’s broader assertion campaign against multiple parties in the consolidated series was not fully resolved by the CVS dismissal.
PatSnap Eureka searches patents and litigation data to answer instantly.